Meeting
2021 ASCO Annual Meeting
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
Authors
Anna Rachel Minchom
Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, United Kingdom
Anna Rachel Minchom , Nicolas Girard , Lyudmila Bazhenova , Sai-Hong Ignatius Ou , Shirish M. Gadgeel , José Trigo , Santiago Viteri , Daniel Backenroth , Archan Bhattacharya , Tracy Li , Parthiv Mahadevia , Joshua Bauml
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9052)
DOI
10.1200/JCO.2021.39.15_suppl.9052
Abstract #
9052
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee
First Author: Zofia Piotrowska
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya